<DOC>
	<DOC>NCT00004293</DOC>
	<brief_summary>OBJECTIVES: I. Evaluate the efficacy and toxicity of glucocerebrosidase enzyme therapy in patients with Gaucher disease.</brief_summary>
	<brief_title>Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease</brief_title>
	<detailed_description>PROTOCOL OUTLINE: Patients are treated with intravenous glucocerebrosidase every 2 weeks. The dose is based on clinical severity of disease and response to therapy.</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Gaucher disease with glucocerebrosidase deficiency confirmed by enzymatic or molecular assay At least 3 organ systems affected, based on the following criteria: Anemia Thrombocytopenia Organomegaly Bone deterioration on radiograph Pulmonary compromise Symptoms compromise daily activities or risk longevity No neurologic disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2003</verification_date>
	<keyword>Gaucher's disease</keyword>
	<keyword>inborn errors of metabolism</keyword>
	<keyword>rare disease</keyword>
	<keyword>sphingolipidoses</keyword>
</DOC>